CFR section
21 CFR 1271.350(a)(1): Reporting
PART 1271-HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS · Subpart E-Additional Requirements for Establishments Described in § 1271.10
Key facts
| Citation | 21 CFR 1271.350(a)(1) |
|---|---|
| Section | Reporting |
| Part | PART 1271-HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS |
| Subpart | Subpart E-Additional Requirements for Establishments Described in § 1271.10 |
| Subchapter | 21 CFR L Other |
| Product types cited | Drugs, Other_Regulations |
| Regulation text (excerpt) | (1) You must investigate any adverse reaction involving a communicable disease related to an HCT/P that you made available for distribution. You must report to FDA an adverse reaction involving a communicable disease if it: (i) Is fatal; (ii) Is life-threatening; (iii) Results in permanent impairment of a body function or permanent damage to body structure; or (iv) Necessitates medical or surgical intervention, including hospitalization. |
At a glance
- 1–9 Inspections citing this section
- 1–9 Warning letters citing this section
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About CFR sections cited by the FDA
Title 21 of the Code of Federal Regulations contains the FDA's regulations, including current good manufacturing practice and quality system requirements that inspections cite.